IL17A and COVID-19: The authors also demonstrated that, while IL-17A is not considered a good marker for disease severity, it is capable of activating inflammatory pathways that may result in tissue damage and exacerbation of disease, meaning it likely plays a deleterious role in COVID-19 pathogenesis.